Literature DB >> 11775012

Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gamma-dependent RANTES production following a vaginal viral challenge.

A M Harandi1, B Svennerholm, J Holmgren, K Eriksson.   

Abstract

PROBLEM: To investigate the production of the CC chemokines RANTES. MCP-1, and MlP-1alpha in the vaginal mucosa following HSV-2 challenge in vaccinated and unvaccinated mice. METHOD OF STUDY: The concentrations of the chemokines were determined in the vagina of HSV-2-vaccinated as well as unvaccinated mice after HSV-2 challenge using a PERFEXT method combined with ELISA.
RESULTS: HSV-2 infection did not induce any measurable levels of MIP-1alpha, whereas high levels of RANTES and MCP-1 were detected in unvaccinated animals at 48 hr post challenge. The vaccinated mice developed a more rapid induction of RANTES, but not of MCP-1, appearing as early as 24 hr post challenge. The local induction of RANTES production was preceded by a vaginal IFN-gamma response. Furthermore, vaccinated IFN-gamma-/- mice did not produce any enhanced levels of RANTES following HSV-2 challenge.
CONCLUSIONS: The protective immune response against genital HSV-2 infection is associated with a rapid induction of local IFN-gamma-dependent RANTES production.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11775012     DOI: 10.1034/j.1600-0897.2001.d01-34.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  13 in total

Review 1.  Herpes simplex virus and the chemokines that mediate the inflammation.

Authors:  D J J Carr; L Tomanek
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

2.  Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Authors:  Staffan Görander; Ali M Harandi; Madelene Lindqvist; Tomas Bergström; Jan-Åke Liljeqvist
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

3.  Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.

Authors:  Christopher D Conrady; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

4.  Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue.

Authors:  Amy E Gillgrass; Vera A Tang; Kate M Towarnicki; Kenneth L Rosenthal; Charu Kaushic
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

Authors:  Ali A Ashkar; Stefan Bauer; William J Mitchell; Jeff Vieira; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels.

Authors:  Edward R Cachay; Simon D W Frost; Art F Y Poon; David Looney; Sherry M Rostami; Mary E Pacold; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

7.  CXCR3 deficiency increases susceptibility to genital herpes simplex virus type 2 infection: Uncoupling of CD8+ T-cell effector function but not migration.

Authors:  Manoj Thapa; Daniel J J Carr
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

Review 8.  Applications of chemokines as adjuvants for vaccine immunotherapy.

Authors:  Teena Mohan; Wandi Zhu; Ye Wang; Bao-Zhong Wang
Journal:  Immunobiology       Date:  2017-12-08       Impact factor: 3.144

9.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099

10.  A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.

Authors:  Federica Crostarosa; Meropi Aravantinou; Onome J Akpogheneta; Edith Jasny; Andrew Shaw; Jessica Kenney; Michael Piatak; Jeffrey D Lifson; Aaron Teitelbaum; Lieyu Hu; Anne Chudolij; Thomas M Zydowsky; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.